Business & FinanceTop StoryTop StoryLatest News
Glenmark Pharma Q2 Revenue Falls 30% to ₹4,247 Crore, Profit Down 57%
Sentiment: NegativeHigh Priority
What Happened?
Glenmark Pharmaceuticals reported a 56.78% drop in consolidated profit after tax to ₹263.83 crore for Q2, down from ₹610.43 crore last year. Total revenue fell to ₹4,247.32 crore from ₹6,046.87 crore.
Key points
- Consolidated profit after tax fell to ₹263.83 crore in Q2.
- Total revenue from operations decreased to ₹4,247.32 crore.
- Total expenses dropped to ₹3,627.70 crore.
- Glenmark USA settled with Humana Inc for USD 15 million.
- Chairman Glenn Saldanha stated growth is expected in India and North America.
Key insights
- The decline in profit may lead to increased scrutiny from investors.
- Future growth in North America could hinge on successful product launches.
- The settlement with Humana Inc may affect Glenmark's legal standing.
Why it matters
The significant drop in revenue and profit could impact investor confidence in Glenmark Pharmaceuticals.
Tags
Entities
Glenmark Pharmaceuticals· CompanyHumana Inc· Company
Source
Business Standard
